Orphan drug regulation: a global comparison of the United States Food and Drug Administration, European Medicines Agency, and Japanese Pharmaceuticals and Medical Devices Agency approaches.
TL;DR
A comparative review of orphan drug policies and designation criteria implemented by the US Food and Drug Administration, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency is performed, assessing their influence on development, approval, and access.
Abstract
Objective
To perform a comparative review of orphan drug policies and designation criteria implemented by the US Food and Drug Administration, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency, assessing their influence on development, approval, and access.
Method
A targeted review of legislation, guidance documents, and peer-reviewed analyses from each regulatory body was conducted.
Results
The Food and Drug Administration accelerates development via robust tax credits and seven-year market exclusivity, though high pricing remains challenging. The European Medicines Agency emphasizes unmet medical needs and ten-year exclusivity, ensuring more homogeneous pricing despite slower approvals. Japan's Pharmaceuticals and Medical Devices Agency utilizes specific subsidies and the "Sakigake" designation to counter "drug loss" and encourage innovation. Despite expedited pathways globally, significant disparities in affordability and patient access persist.
Conclusions
While national incentives successfully boost orphan drug approvals, global access inequities remain unresolved. Harmonizing regulatory criteria and promoting international collaboration on evidence requirements are essential for equitable and sustainable access to rare disease therapies worldwide.